Novartis (NVS) stock popped Tuesday on a solid second-quarter report, despite feeling continued heat from generic rivals for big-name drugs like Entresto and Xolair. In total, sales grew 3% to $14.41 billion, easily topping expectations for $14.07 billion, according to FactSet. Excluding the impact of exchange rates, sales ticked 1% higher. But, while volume contributed 18 percentage points to that…
Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8